Revolution Medicines, Inc., a clinical-stage precision oncology company, focuses on developing therapies to inhibit frontier targets in RAS-addicted cancers. The company is developing RMC-4630, an inhibitor of SHP2, which is in Phase 1/2 clinical trial for the treatment of solid tumors, such as gynecologic and colorectal cancer tumors. It also develops RMC-5845, a selective inhibitor of SOS1, a protein that converts RAS (OFF) to RAS (ON) in cells; and RMC-5552, a hyperactivated selective inhibitor of mTORC1 signaling in tumors. In addition, the company is developing RMC-6291, a mutant-selective inhibitor of KRASG12C(ON) and NRASG12C(ON); and RMC-6236, a RAS-selective inhibitor of multiple RAS(ON) variants. Further, it develops RAS(ON) Inhibitors targeting KRASG13C(ON) and KRASG12D(ON). Revolution Medicines, Inc. has a collaboration agreement with Sanofi for the research and development of SHP2 inhibitors, including RMC-4630. The company was incorporated in 2014 and is headquartered in Redwood City, California.
IPO Year: 2020
Exchange: NASDAQ
Website: revmed.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 7/16/2024 | $46.00 → $62.00 | Buy | Needham |
| 7/12/2024 | $52.00 | Overweight | Barclays |
| 7/8/2024 | $63.00 | Buy | Jefferies |
| 4/12/2024 | $36.00 → $46.00 | Buy | Needham |
| 4/10/2024 | $36.00 → $48.00 | Outperform → Strong Buy | Raymond James |
| 3/11/2024 | $43.00 | Overweight | Piper Sandler |
| 1/5/2024 | $31.00 → $34.00 | Neutral → Buy | BofA Securities |
| 1/4/2024 | $41.00 | Outperform | Wedbush |
| 11/16/2023 | $30.00 | Outperform | Raymond James |
| 2/28/2023 | $32.00 → $38.00 | Neutral → Overweight | JP Morgan |
8-K - Revolution Medicines, Inc. (0001628171) (Filer)
144 - Revolution Medicines, Inc. (0001628171) (Subject)
144 - Revolution Medicines, Inc. (0001628171) (Subject)
144 - Revolution Medicines, Inc. (0001628171) (Subject)
144 - Revolution Medicines, Inc. (0001628171) (Subject)
SCHEDULE 13G/A - Revolution Medicines, Inc. (0001628171) (Subject)
SCHEDULE 13G/A - Revolution Medicines, Inc. (0001628171) (Subject)
SCHEDULE 13G - Revolution Medicines, Inc. (0001628171) (Subject)
SCHEDULE 13G/A - Revolution Medicines, Inc. (0001628171) (Subject)
10-Q - Revolution Medicines, Inc. (0001628171) (Filer)
REDWOOD CITY, Calif., May 14, 2025 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (NASDAQ:RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced the first patient has been dosed in RASolve 301, a global, randomized, open-label Phase 3 clinical trial. RASolve 301 will evaluate the safety and efficacy of daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor, in patients with previously treated, locally advanced or metastatic RAS mutant non-small cell lung cancer (NSCLC) compared to docetaxel chemotherapy. RASolve 301 is anticipated to enroll approximately 420 patients with NSCLC worldwide who have received
Strong execution of two ongoing Phase 3 trials of daraxonrasib; company expects to substantially complete enrollment of RASolute 302 in patients with pancreatic cancer this yearNew non-small cell lung cancer clinical data from RAS(ON) inhibitor portfolio support strategies for first-line metastatic and earlier lines of treatmentAnthony Mancini joins as chief global commercialization officerRevolution Medicines to hold webcast today at 4:30 p.m. Eastern Time REDWOOD CITY, Calif., May 07, 2025 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (NASDAQ:RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced its financial
REDWOOD CITY, Calif., April 30, 2025 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (NASDAQ:RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced that it will report financial results for the first quarter of 2025 on Wednesday, May 7, 2025, after market close. At 4:30 p.m. ET that day (1:30 p.m. PT), members of Revolution Medicines' senior management team will host a webcast to discuss the financial results for the quarter and provide an update on corporate progress. To listen to the live webcast, or access the archived webcast, please visit: https://ir.revmed.com/events-and-presentations. Following the live web
Garching / Munich, Germany, April 09, 2025 – ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, today announced the election of Barbara Weber, M.D., to its Supervisory Board, effective May 01, 2025. The election occurred at ITM's Extraordinary General Meeting. Dr. Weber is the President, Chief Executive Officer and Founder of Tango Therapeutics (NASDAQ:TNGX). She has over 25 years of executive and research and development leadership experience in biotech, venture capital and at major pharmaceutical companies, including Novartis (NYSE:NVS) and GlaxoSmithKline (NYSE:GSK). ITM's Supervisory Board and the company overall will benefit from Dr. Weber's deep ex
REDWOOD CITY, Calif., March 31, 2025 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (NASDAQ:RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced that Mark A. Goldsmith, M.D., Ph.D., the company's chief executive officer and chairman, will participate in in two upcoming investor conferences. Details of the company's participation are as follows: Needham 24th Annual Virtual Healthcare Conference Fireside Chat: Monday, April 7 at 2:15 p.m. ET Stifel 2025 Virtual Targeted Oncology Forum Fireside Chat: Wednesday, April 9 at 1:00 p.m. ET To listen to a live webcast of any of these events, or access archived webc
Company anticipates substantially completing enrollment this year in ongoing Phase 3 RASolute 302 trial of daraxonrasib in previously treated metastatic pancreatic cancer to enable expected data readout in 2026Company is activating study sites for Phase 3 RASolve 301 trial of daraxonrasib in previously treated locally advanced or metastatic RAS mutant non-small cell lung cancerCompany anticipates initiating two additional registrational trials of daraxonrasib in earlier lines of treatment for pancreatic cancer in the second half of 2025Revolution Medicines to hold webcast today at 4:30 p.m. Eastern Time REDWOOD CITY, Calif., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (NA
REDWOOD CITY, Calif., Feb. 24, 2025 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (NASDAQ:RVMD), a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers, today announced that Mark A. Goldsmith, M.D., Ph.D., the company's chief executive officer and chairman, will participate in three upcoming investor conferences. Details of the company's participation are as follows: TD Cowen 45th Annual Healthcare Conference Fireside Chat Date/Time: Monday, March 3 at 1:50 p.m. ET Barclays 27th Annual Global Healthcare Conference Fireside Chat Date/Time: Tuesday, March 11 at 8:00 a.m. ET 2025 Leerink Partners Global Healthcare Conference Fi
REDWOOD CITY, Calif., Feb. 19, 2025 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (NASDAQ:RVMD), a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers, today announced that it will report financial results for the fourth quarter and full year 2024 on Wednesday, February 26, 2025, after market close. At 4:30 p.m. ET that day (1:30 p.m. PT), members of Revolution Medicines' senior management team will host a webcast to discuss the financial results for the quarter and full year and provide an update on corporate progress. To listen to the live webcast, or access the archived webcast, please visit: https://ir.revmed.com/events-an
REDWOOD CITY, Calif., Jan. 29, 2025 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (NASDAQ:RVMD), a clinical-stage oncology company developing novel targeted therapies for patients with RAS-addicted cancers, today announced that Mark A. Goldsmith, M.D., Ph.D., the company's chief executive officer and chairman, will participate in a fireside chat as part of the Guggenheim Securities SMID Cap Biotech Conference on Wednesday, February 5, 2025, at 10:30 a.m. ET. To access the live webcast of the presentation, please visit the "Events & Presentations" page of Revolution Medicines' website at https://ir.revmed.com/events-and-presentations. Additionally, a replay of the webcast will be availabl
REDWOOD CITY, Calif., Jan. 06, 2025 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (NASDAQ:RVMD), a clinical-stage oncology company developing novel targeted therapies for patients with RAS-addicted cancers, today announced that Mark A. Goldsmith, M.D., Ph.D., the company's chief executive officer and chairman, will deliver a corporate presentation as part of the 43rd Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2025 at 10:30 a.m. PT. To access the live webcast of the presentation, please visit the "Events & Presentations" page of Revolution Medicines' website at https://ir.revmed.com/events-and-presentations. Additionally, a replay of the webcast will be available on t